Brenus Pharma, a biotech company specialized in the development of new generations of allogeneic cell-based immunotherapies supported by MATWIN in 2021, and InSphero AG, a pioneer in 3D cell-based assays and organ-on-a-chip technology, announced today that they have received a €1.5 million grant for the collaborative project “STC-1010 : A First-in-Class Allogeneic Cell Vaccine Against Cancer”, which aims to use 3D cell culture to develop a novel cell immunotherapy for colorectal cancer.
Read the press release :
